In addition, elevated estrogen byproducts resulting from all three metabolic pathways were associated with increased ER-/PR- breast cancer risk; however, the relative amounts of 2-pathway metabolites to 16-hydroxylation pathway metabolites, which have been previously linked to postmenopausal breast cancer risk, were not. This evidence concerns the gene ESR1 and breast cancer.